share_log

HC Wainwright & Co. Downgrades TherapeuticsMD to Neutral, Announces $10 Price Target

HC Wainwright & Co. Downgrades TherapeuticsMD to Neutral, Announces $10 Price Target

HC Wainwright & Co.将TherapeuticSMD的评级下调至中性,宣布10美元的目标股价
Benzinga Real-time News ·  2022/06/07 07:24

HC Wainwright & Co. analyst Douglas Tsao downgrades TherapeuticsMD (NASDAQ:TXMD) from Buy to Neutral and announces $10 price target.

HC Wainwright & Co. 分析师曹道格拉斯将TherapeuticSMD(纳斯达克股票代码:TXMD)的评级从买入下调至中性,并宣布了10美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发